Cellular transport and lipid interactions of Miltefosine

Current Drug Metabolism

Volumn 10, Issue 3, 2009, Pages 247-255

  Barratt, Gillian ^a,b   Saint Pierre Chazalet, Michèle ^b,c,d   Loiseau, Philippe Marie ^b,e  

^a UNIV PARIS SUD   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d CNRS   (France)

^e UNIVERSITÉ PARIS SUD   (France)

Author keywords

Alkyl phospholipids; Cell membrane; Cholesterol; Hexadecylphosphocholine; Leishmania; Lipid rafts; Miltefosine; Phospholipids

Indexed keywords

AMINOPHOSPHOLIPID TRANSLOCASE; CARRIER PROTEIN; CERAMIDE; CHOLESTEROL; DOXORUBICIN; LIPOSOME; MACROGOL; MEMBRANE LIPID; MILTEFOSINE; PHOSPHOLIPASE A2; PHOSPHOLIPASE C; PHOSPHOLIPASE D; PHOSPHOLIPID; PROTEIN KINASE C; STERICALLY STABILIZED LIPOSOME; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; CANCER CELL; CELL MEMBRANE TRANSPORT; CELL TRANSPORT; CELL VIABILITY; CHOLESTEROL METABOLISM; CYTOTOXICITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TRANSPORT; DRUG UPTAKE; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; INTESTINE CELL; LEISHMANIA; LEISHMANIA DONOVANI; LIPID COMPOSITION; LIPID METABOLISM; LIPID MONOLAYER; LIPID RAFT; LIPOSOMAL DELIVERY; MACROPHAGE ACTIVATION; MEMBRANE DAMAGE; NONHUMAN; PHOSPHOLIPID METABOLISM; PROTEIN LIPID INTERACTION; PROTEIN LOCALIZATION; REVIEW; SKIN METASTASIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; ENTEROCYTES; HUMANS; LEISHMANIA; LIPOSOMES; MEMBRANE LIPIDS; PHOSPHORYLCHOLINE;

EID: 65549098612     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009787846332     Document Type: Review

References (105)

1. Soto, J.; Berman, J. Treatment of New World cutaneous leishmaniasis with miltefosine. Trans. R. Soc. Trop. Med. Hyg., 2006, 100 (Suppl 1), S34-40.
2. Rakotomanga, M.; Loiseau, P.M.; Saint-Pierre-Chazalet, M. Hexadecylphosphocholine interaction with lipid monolayers, Biochim. Biophys. Acta., 2004, 1661, 212-218.
3. Rey Gomez-Serranillos, I.; Minones Jr. J.; Dynarowicz-Lakta, P.; Minones, J.; Iribarnegaray, E. Miltefosine-cholesterol interactions: a monolayer study. Langmuir, 2004, 20, 928-933.
4. Rey Gomez-Serranillos, I.; Minones Jr. J.; Dynarowicz-Lakta, P.; Minones, J.; Conde O. Surface behavior of oleoyl palmitoyl phosphatidyl ethanolamine (OPPE) and the characteristics of mixed OPPE-miltefosine monolayers. Langmuir, 2004, 20, 11414-11421.
5. Rakotomanga, M.; Saint-Pierre-Chazalet, M.; Loiseau, P.M. Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions. Antimicrob. Agents Chemother., 2005, 49, 2677-2686.
6. Chapman, D.; Owens N.F.; Phillips, M.C.; Walker, D.A. Mixed monolayers of phospholipids and cholesterol. Biochim. Biophys. Acta., 1969, 183, 458-465.
7. Ghosh, D.; Tinoco J. Monolayer interactions of individual lecithins with natural sterols. Biochim. Biophys. Acta., 1972, 266, 41-49.
8. Mozaffary, H. Cholesterol-phospholipid interaction: a monolayer study. Thin Solid Films, 1994, 244, 874-877.
9. Saint-Pierre-Chazalet, M.; Thomas C.; Dupeyrat, M.; Gary-Bobo, C.M. Amphotericin B-sterol complex formation and competition with egg phosphatidylcholine: a monolayer study. Biochim. Biophys. Acta., 1988, 944, 477-486.
10. Minones, Jr. J.; Rez Gomez-Serranillos, I.; Conde, O.; Dynarowicz-Latka, P.; Minones Trillo, J. The influence of subphase temperature on miltefosine-cholesterol mixed monolayers. J. Colloid Interface Sci., 2006, 301, 258-260.
11. Heczkova, B.; Slotte, J.P. Effect of anti-tumor ether lipids on ordered domains in model membranes. FEBS Lett., 2006, 580, 2471-2476.
12. Mravljak, J.; Zeisig, R.; Pečar, S. Synthesis and biological evaluation of spin-labeled alkylphospholipid analogs. J. Med. Chem., 2005, 48, 6393-6399.
13. Heesbeen, E.C.; Verdonck, L.F.; Haagmans, M.; van Heugten, H.G.; Staal, G.E.; Rijksen, G. Adsorption and uptake of the alkyl-lysophospholipid ET-18-OCH3 by HL-60 cells during induction of differentiation by dimethylsulfoxide. Leuk. Res., 1993, 17, 143-148.
14. Storch, J.; Munder, P.G. Increased membrane permeability for an antitumoral alkyl lysophospholipid in sensitive tumor cells. Lipids, 1987, 22, 813-819.
15. Zoeller, R.A.; Layne, M.D.; Modest, E.J. Animal cell mutants unable to take up biologically active glycerophospholipids. J. Lipid Res., 1995, 36, 1866-1875.
16. Geilen C.C.; Wieder, T.; Haase, R.; Reutter, W.; Morre, D.M.; Morre, D.J. Uptake, subcellular distribution and metabolism of the phospholipid analogue hexadecylphosphocholine in MDCK cells. Biochim. Biophys. Acta., 1994, 1211, 14-22.
17. Fleer, E.A.; Berkovic, D.; Unger, C.; Eibl, H. Cellular uptake and metabolic fate of hexadecylphosphocholine. Prog. Exp. Tumor Res., 1992, 34, 33-46.
18. Fleer, E.A.; Berkovic D.; Eibl, H.; Unger, C. Investigations on the cellular uptake of hexadecylphosphocholine. Lipids, 1993, 28, 731-736.
19. Brochez, V.; van Heuverswyn, D.; Diniz, J.A.; de B.N.F.; De Potter, C.R.; van den Eeckhout, E.G. Cellular uptake and retention measurements of alkylphosphocholines in the SK-BR-3 breast cancer and Molt-4 leukemia cell line using capillary gas chromatography. Lipids, 1999, 34, 511-516.
20. Steelant, W.F.A.; Bruyneel, E.A.; Mareel, M.M.; van den Eeckhout, E.G. Capillary gas chromatography of hexadecylphosphocholine in Caco-2T cells and cell culture media. Anal. Biochem. 1995, 227, 246-250.
21. Zheng, B.; Oishi, K.; Shoji, M.; Eibl, H.; Berdel, W.E.; Hajdu, J.; Vogler, W.R.; Kuo, J.F. Inhibition of protein kinase C, (sodium plus potassium)-activated adenosine triphosphatase, and sodium pump by synthetic phospholipid analogues. Cancer Res., 1990, 50, 3025-3031.
22. Geilen, C.C.; Haase, R.; Buchner, K.; Wieder, T.; Hucho, F., Reutter, W. The phospholipid analogue, hexadecylphosphocholine, inhibits protein kinase C in vitro and antagonises phorbol ester-stimulated cell proliferation. Eur. J. Cancer, 1991, 27, 1650-1653.
23. Uberall, F.; Oberhuber, H.; Maly, K.; Zaknun, J.; Demuth, L.; Grunicke, H.H. Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res., 1991, 51, 807-812.
24. Wieder, T.; Zhang, Z.; Geilen, C.C.; Orfanos, C.E.; Guiliano, A.E.; Cabot, M.C. The antitumor phospholipid analog, hexadecylphosphocholine, activates cellular phospholipase D. Cancer Lett., 1996, 100, 71-79.
25. Ruiter, G.A.; Verheij, M.; Zerp, S.F.; van Blitteerswijk, W.J. Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis. Int. J. Radiat. Oncol. Biol. Phys., 2001, 49, 415-419.
26. Haase, R.; Wieder,T.; Geilen, G.C.; Reutter, W. The phospholipid analogue hexadecylphosphocholine inhibits phosphatidylcholine biosynthesis in Madin-Darby canine kidney cells. FEBS Lett., 1991, 288, 129-132.
27. Boggs, K.P.; Rock, C.O.; Jackowski, S. Lysophosphatidylcholine attenuates the cytotoxic effects of the antineoplastic phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3- phosphocholine. J. Biol. Chem., 1995, 270, 11612-11618.
28. Van der Luit, A.H.; Budde, M.; Verheij, M.; Van Blitterswijk, W.J. Different modes of internalization of apoptotic alkyl-lysophospholipid and cell-rescuing lysophosphatidylcholine. Biochem. J., 2003, 374, 747-758.
29. Van der Sanden M.H.M.; Houweling M.; Duisjsings D.; Vaandrager, A.B., van Golde, L.M.G. Inhibition of phosphatidylcholine synthesis is not the primary pathway in hexadecylphosphocholine-induced apoptosis Biochim. Biophys. Acta., 2004, 1636, 99-107.
30. Berkovic, D.; Sievers, S.; Haase, D.; Fleer, E.A.; Binder, C. Effects of hexadecylphosphocholine on phosphatidylcholine and phosphatidylserine metabolism in human lymphoma cells. J. Exp. Ther. Oncol., 2002, 2, 85-92.
31. Berkovic, D.; Grunwald, U.; Menzel, W.; Unger, C.; Hiddemann, W.; Fleer, E.A.M. Effects of hexadecylphosphocholine on membrane phospholipid metabolism in human tumour cells. Eur. J. Cancer, 1995, 31A, 2080-2085.
32. Diomede, L.; Bizzi, A.; Magistrelli, A.; Modest, E.J.; Salmona, M.; Noseda, A. Role of cell cholesterol in modulating antineoplastic ether lipid uptake, membrane effects and cytotoxicity. Int. J. Cancer, 1990, 46, 341-346.
33. Zufferey R.; Mamoun C.B. Choline transport in Leishmania major promastigotes and its inhibition by choline and phosphocholine analogs. Mol. Biochem. Parasitol., 2002, 125, 127-134.
34. Lux, H.; Heise, N.; Klenner, T.; Hart, D.; Opperdoes, F.R. Etherlipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Mol. Biochem. Parasitol., 2000, 111, 1-14.
35. Rakotomanga, M.; Blanc, S.; Gaudin, K.; Chaminade, P.; Loiseau, P.M. Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. Antimicrob. Agents Chemother., 2007, 51, 1425-1430.
36. Lira, R.; Contreras, L.M.; Rita, R.M.; Urbina, J.A. Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole. J. Antimicrob. Chemother., 2001, 47, 537-546.
37. Jiménez-López, J.M.; Carrasco, M.P.; Segovia, J.L.; Marco, C. Hexadecylphosphocholine inhibits phosphatidylcholine synthesis via both the methylation of phosphatidylethanolamine and CDP-choline pathways in HepG2 cells. Int. J. Biochem. Cell. Biol., 2004, 36, 153-161.
38. Teshima, K.; Ikeda, K.; Hamaguchi, K.; Hayashi, K. Bindings of cobra venom phospholipases A2 to micelles of n-hexadecylphosphorylcholine. J. Biochem. (Tokyo), 1983, 94, 223-232.
39. Mao, S.Y.; Maki, A.H.; de Haas, G.H. Investigation of phospholipase-lipid interactions by optical detection of triplet state magnetic resonance spectroscopy. FEBS Lett., 1985, 185, 71-75.
40. Mao, S.Y.; Maki, A.H.; de Haas, G.H. Comparative optically detected magnetic resonance studies of mammalian phospholipase A2-lipid interactions. FEBS Lett., 1987, 211, 83-88.
41. Ikeda, K.; Sano, S.; Teshima, K.; Samejima, Y. pH dependence of the binding constant of a phospholipase A2 from Agkistrodon halys blomhoffii venom to micelles of n-hexadecylphosphorylcholine. J. Biochem. (Tokyo), 1984, 96, 1427-1436.
42. Berkovic, D.; Lüders, S.; Goeckenjan, M.; Hiddemann, W.; Fleer, E.A.M. Differential regulation of phospholipase A2 in human leukemia cells by the etherphospholipid analogue hexadecylphosphocholine. Biochem. Pharmacol., 1997, 53, 1725-1733.
43. Lucas, L.; Hernandez-Alcoceba, R.; Penalva, V.; Lacal, J.C. Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity. Oncogene, 2001, 20, 1110-1117.
44. Berkovic, D.; Berkovic, K.; Binder, C.; Haase, D.; Fleer, E.A. Hexadecylphosphocholine does not influence phospholipase D and sphingomyelinase activity in human leukemia cells. J. Exp. Ther. Oncol., 2002, 2, 213-218.
45. Berkovic, D.; Wernicke, J.H.; Fleer, E.A. Effects of etherlipid analogs on cell membrane functions. J. Exp. Ther. Oncol., 2003, 3, 185-193.
46. Jiménez-Lopez, J.M.; Carrasco, M.P.; Marco, C.; Segovia, J.L. Hexadecylphosphocholine disrupts cholesterol homeostasis and induces the accumulation of free cholesterol in HepG2 tumour cells. Biochem. Pharmacol., 2006, 71, 1114-1121.
47. Mbongo, N.; Loiseau, P.M.; Billion, M.A.; Robert-Gero, M. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob. Agents Chemother., 1998, 42, 352-357.
48. Cauchetier, E.; Loiseau, P.M.; Lehman, J.; Rivollet, D.; Fleury, J.; Astier, A.; Deniau, M.; Paul, M. Characterisation of atovaquone resistance in Leishmania infantum promastigotes. Int. J. Parasitol., 2002, 32, 1043-1051.
49. Wieder, T.; Orfanos, C.E.; Geilen C. Induction of ceramide-mediated apoptosis by the anticancer phospholipid analog, hexadecylphosphocholine. J. Biol. Chem., 1998, 273, 11025-11031.
50. Paris, C.; Loiseau, P.M.; Bories, C.; Bréard, J. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob. Agents Chemother., 2004, 48, 852-859.
51. Verma N.K.; Dey, C.S. Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob. Agents Chemother., 2004, 48, 3010-3015.
52. Ruiter, G.A.; Zerp, S.P.; Bartelink, H.; van Blitterswijk, W.J.; Verheij, M. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs, 2003, 14, 167-173.
53. Verma, N.K.; Dey, C.S. The anti-leishmanial drug miltefosine causes insulin resistance in skeletal muscle cells in vitro. Diabetologia, 2006, 49, 1656-1660.
54. Verma, N.K.; Singh, G.; Dey, C.S. Miltefosine induces apoptosis in arsenite-resistant Leishmania donovani promastigotes through mitochondrial dysfunction. Exp. Parasitol., 2007, 116, 1-13.
55. Luque-Ortega, J.R.; Rivas, L. Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes. Antimicrob. Agents Chemother., 2007, 51, 1327-1332.
56. Settelen, N.; Roch, O.; Bock, D.; Rooke, R.; Braun, S.; Meyer, O. Controlled plasmid gene transfer to murine renal carcinoma by hexadecylphosphocholine. J. Control. Release, 2004, 94, 237-244.
57. Pérez-Victoria, F.J.; Castanys, S.; Gamarro, F. Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug. Antimicrob. Agents Chemother., 2003, 47, 2397-2403.
58. Pérez-Victoria, F.J.; Gamarro, F.; Ouellette, M.; Castanys, S. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J. Biol. Chem., 2003, 278, 49965-49971.
59. Saugar, J.M.; Delgado, J.; Hornillos, V.; Luque-Ortega, J.R.; Amat-Guerri, F.; Acuña, A.U.; Rivas, L. Synthesis and biological evaluation of fluorescent leishmanicidal analogues of hexadecylphosphocholine (miltefosine) as probes of antiparasite mechanisms. J. Med. Chem., 2007, 50, 5994-6003.
60. Seifert, K.; Pérez-Victoria, F.J.; Stettler, M.; Sanchez-Cañete, M.P.; Castanys, S.; Gamarro, F.; Croft, S.L. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int. J. Antimicrob. Agents, 2007, 30, 229-235.
61. Pérez-Victoria, F.J.; Sánchez-Cañete, M.P.; Castanys, S.; Gamarro, F. Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites. J. Biol. Chem., 2006, 281, 23766-23775.
62. Perez-Victoria, J.M.; Cortés-Selva, F., Parodi-Talice, A.; Bavchvarov, B.I., Pérez-Victoria, F.J.; Muñoz-Martínez, F.; Maitrejean, M.; Costi, M.P.; Barron, D.; Di Pietro, A.; Castanys, S.; Gamarro, F. Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to Miltefosine by inhibiting drug efflux. Antimicrob. Agents Chemother., 2006, 50, 3102-3110.
63. Castanys-Muñoz, E.; Alder-Baerens, N.; Pomorski, T.; Gamarro, F.; Castanys, S. novel ATP-binding cassette transporter from Leishmania is involved in transport of phosphatidylcholine analogues and resistance to alkyl-phospholipids. Mol. Microbiol., 2007, 64, 1141-1153.
64. Zentaris-AG. Impavido registration certificate for Miltefosine capsules 10 mg and 50 mg, Issued by German registration authority, November 19, 2004.
65. Arnold, B.; Reuther, R.; Weltzien, H.U. Distribution and metabolism of synthetic alkyl analogs of lysophosphatidylcholine in mice. Biochim. Biophys. Acta., 1978, 530, 47-55.
66. Breiser, A.; Kim, D.J.; Fleer, E.A.; Damenz, W.; Drube, A.; Berger, M.; Nagel, G.A.; Eibl, H.; Unger, C. Distribution and metabolism of hexadecylphosphocholine in mice. Lipids, 1987, 22, 925-926.
67. Ménez, C.; Buyse, M.; Chacun, H.; Farinotti, R.; Barratt, G. Modulation of intestinal barrier properties by miltefosine. Biochem. Pharmacol., 2006, 71, 486-496.
68. Castro, A.F.; Horton, J.K.; Vanoye, C.G.; Altenberg, G.A. Mechanism of inhibition of P-glycoprotein-mediated drug transport by protein kinase C blockers. Biochem. Pharmacol. 1999, 58, 1723-1733.
69. Rybczynska, M.; Liu, R.; Lu, P.; Sharom, F.J.; Steinfels, E.; Di Pietro, A.; Spitaler, M.; Grunicke H.; Hofmann, A. MDR1 causes resistance to the antitumour drug miltefosine. Br. J. Cancer, 2001, 84, 1405-1411.
70. Márián, T.; Balkay, L.; Trón, L.; Krasnai, Z.T.; Szabó, J.; Krasnai, Z. Effects of miltefosine on membrane permeability and accumulation of [99mTc]-hexakis-2-methoxyisobutyl isonitrile, 2-[18F]fluoro-2-deoxy-D-glucose, daunorubucin and rhodamine123 in multidrug-resistant and sensitive cells. Eur. J. Pharm. Sci., 2005, 24, 495-501.
71. Eckford, P.D.W.; Sharom, F.J. P-glycoprotein (ABCB1) interacts directly with lipid-based anti-cancer drugs and platelet-activating factors. Biochem. Cell Biol., 2006, 84, 1022-1033.
72. Leroy, A.; De Bruyne, G.K.; Oomen, L.C.; Mareel, M.M. Alky-lphospholipids reversibly open epithelial tight junctions. Anticancer Res., 2003, 23, 27-32.
73. Liu, D.Z.; LeCluyse, E.L.; Thakker, D.R. Dodecylphosphocholine-mediated enhancement of paracellular permeability and cytotoxicity in Caco-2 cell monolayers. J. Pharm. Sci., 1999, 88, 1161-1168.
74. Schulze, C.; Smales, C.; Rubin, L.L.; Staddon, J.M. Lysophosphatidic acid increases tight junction permeability in cultured brain endothelial cells. J. Neurochem., 1997, 68, 991-1000.
75. Brondsted, H.; Nielsen, H.M.; Hovgaard, L. Drug delivery studies in Caco-2 monolayers. III. Intestinal transport of various vaso-pressin analogues in the presence of lysophosphatidylcholine. Int. J. Pharm., 1995, 114, 151-157.
76. Ward, P.D.; Ouyang, H.; Thakker, D.R. Role of phospholipase C-beta in the modulation of epithelial tight junction permeability. J. Pharmacol. Exp. Ther., 2003, 304, 689-698.
77. Ménez, C.; Buyse, M.; Dugave, C.; Farinotti, R.; Barratt, G. Intestinal absorption of miltefosine: contribution of passive paracellular transport. Pharm. Res., 2007, 24, 546-554.
78. Kotting, J.; Marchner N.W.; Neumuller, W.; Unger, C.; Eibl, H. Hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine: a comparison of hemolytic activity, serum binding and tissue distribution. Prog. Exp. Tumor Res., 1992, 34, 131-142.
79. Ménez, C.; Buyse, M.; Farinotti, R.; Barratt, G. Inward translocation of the phospholipid analogue miltefosine across Caco-2 cell membranes exhibits characteristics of a carrier-mediated process. Lipids, 2007, 42, 229-240.
80. Pomorski, T.; Herrmann, A.; Muller, P.; van Meer, G.; Burger, K. Protein-mediated inward translocation of phospholipids occurs in both the apical and basolateral plasma membrane domains of epithelial cells. Biochemistry, 1999, 38, 142-150.
81. Van der Luit, A.H.; Budde, M.; Ruurs, P.; Verheij, M.; van Blitterswijk, W.J. Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis. J. Biol. Chem., 2002, 277, 39541-39547.
82. Van der Luit, A.H.; Vink, S.R.; Klarenbeek, J.B.; Perissoud, D.; Solary, E.; Verheij, M.; van Blitterswijk, W.J. A new class of anti-cancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol. Cancer Ther., 2007, 6, 2337-2345.
83. Ménez, C.; Buyse, M.; Besnard, M.; Farinotti, R.; Loiseau, P.M.; Barratt, G. Interaction between miltefosine and amphotericin B: consequences for their activities towards intestinal epithelial cells and Leishmania donovani promastigotes in vitro. Antimicrob. Agents Chemother., 2006, 50, 3793-3800.
84. Ménez, C.; Legrand, P.; Rosilio, V.; Lesieur, S.; Barratt, G. Physicochemical characterization of molecular assemblies of miltefosine and amphotericin B. Mol. Pharm., 2007, 4, 281-288.
85. Barratt, G.M. Colloidal drug carriers: achievements and perspectives. Cell. Mol. Life Sci., 2003, 60, 21-37.
86. Zeisig, R.; Fichtner, I.; Arndt, D.; Jungmann, S. Antitumor effects of alkylphosphocholines in different murine tumor models: use of liposomal preparations. Anticancer Drugs, 1991, 2, 411-417.
87. Kauffman-Kolle, P.; Dervs, J.; Berger, M.R.; Kötting, J.; Marschner, N.; Unger, C.; Eibl, H. Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine. Cancer Chemother. Pharmacol., 1994, 34, 393-398.
88. Fichtner, I.; Zeisig, R.; Naundorf, H.; Jungmann, S.; Arndt, D.; Asongwe, G.; Double, J.A.; Bibby, M.C. Antineoplastic activity of alkylphosphocholines (APC) in human breast carcinomas in vivo and in vitro; use of liposomes. Breast Cancer Res. Treat., 1994, 32, 269-279.
89. Zeisig, R.; Jungmann, S.; Fichtner, I.; Daemen, T.; Arndt, D. Cytotoxic effects of alkylphosphocholines or alkylphosphocholine-liposomes and macrophages on tumor cells. Anticancer Res., 1994, 14, 1785-1789.
90. Eue, I.; Zeisig, R.; Arndt, D. Alkylphosphocholine-induced production of nitric oxide and tumor necrosis factor alpha by U 937 cells. J. Cancer Res. Clin. Oncol., 1995, 121, 350-356.
91. Zeisig, R.; Rudolf, M.; Eue, I.; Arndt, D. Influence of hexadecylphosphocholine on the release of tumor necrosis factor and nitroxide from peritoneal macrophages in vitro. J. Cancer Res. Clin. Oncol., 1995, 121, 69-75.
92. Eue, I. Growth inhibition of human mammary carcinoma by liposomal hexadecylphosphocholine: Participation of activated macrophages in the antitumor mechanism. Int. J. Cancer, 2001, 92, 426-433.
93. Eue, I. Hexadecylphosphocholine selectively upregulates expression of intracellular adhesion molecule-1 and class I major histocompatibility complex antigen in human monocytes. J. Exp. Ther. Oncol., 2002, 2, 333-336.
94. Perkins, W.R.; Dause, R.B.; Li, X.; Franklin, J.C.; Cabral-Lilly, D.J.; Zha,Y.; Dank, E.H.; Mayhew, E.; Janoff, A.S. Combination of antitumor ether lipid with lipids of complementary molecular shape reduces its hemolytic activity. Biochim. Biophys. Acta., 1997, 1327, 61-68.
95. Lasic, D.D.; Vallner, J.J.; Working, P.K. Sterically stabilized liposomes in cancer therapy and gene delivery. Curr. Opin. Mol. Ther., 1999, 1, 177-185.
96. Zeisig, R.; Eue, I.; Kosch, M.; Fichtner, I.; Arndt, D. Preparation and properties of sterically stabilized hexadecylphosphocholine (miltefosine)-liposomes and influence of this modification on macrophage activation. Biochim. Biophys. Acta., 1996, 1283, 177-184.
97. Zeisig, R.; Shimada, K.; Hirota, S.; Arndt, D. Effect of sterical stabilization on macrophage uptake in vitro and on thickness of the fixed aqueous layer of liposomes made from alkylphosphocholines. Biochim. Biophys. Acta, 1996, 1285, 237-245.
98. Arndt, D.; Zeisig, R.; Fichtner, I.; Teppke, A.D.; Fahr, A. Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice. Breast Cancer Res. Treat., 1999, 58, 71-80.
99. Arndt, D.; Zeisig, R.; Eue, I.; Sternberg, B.; Fichtner, I. Antineoplastic activity of sterically stabilized alkylphosphocholine liposomes in human breast carcinomas. Breast Cancer Res. Treat., 1997, 43, 237-246.
100. Kaufmann-Kolle, P.; Kuhlencord, A.; Eibl, H. Intravenous treatment of Leishmania donovani infected mice with liposomal hexadecylphosphocholine. Cell. Mol. Biol. Lett., 1996, 1, 429-437.
101. Seifert, K.; Duchêne, M.; Wernsdorfer, W.H.; Kollaritsch, H.; Scheiner, O.; Weidermann, G.; Hottkowitz; Eibl, H. Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica. Antimicrob. Agents Chemother., 2001, 45, 1505-1510.
102. Papagiannaros, A.; Bories, C.; Demetzos, C.; Loiseau, P.M. Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations. Biomed. Pharmacother., 2005, 59, 545-550.
103. Papagiannaros, A.; Hatziantoniou, S.; Dimas, K.; Papaionnou, G.T.; Demetzos, C. Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations. Biomed. Pharmacother., 2006, 60, 36-42.
104. Papagiannaros, A.; Hatziantoniou, S.; Lelong-Rebel, I.H.; Papaionnou, G.T.; Dimas, K.; Demetzos, C. Antitumor activity of doxorubicin encapsulated in hexadecylphosphocholine (HePC) liposomes against human xenografts on Scid mice. In Vivo, 2006, 20, 129-135.
105. Lindner, L.H.; Hossann, M.; Vogeser, M.; Teichert, N.; Wachholz, K.; Eibl, H.; Hiddemann, W.; Issels, R.D. Dual role of hexadecylphosphocholine (miltefosine) in thermosensitive liposomes: Active ingredient and mediator of drug release. J. Control. Release, 2008, 125, 112-120.